★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Cochlear Limited (COH) Moat Analysis
Cochlear Limited
COH · ASX
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Cochlear reports Implants, Services and Acoustics, at 61.2%, 27.1% and 11.7% of FY2026 revenue. Its strongest moats are reliability trust, long implant-development cycles and a proprietary recipient base that buys compatible processors and accessories. Nexa reached more than 95% of developed-market implant sales by June and achieved an average 3% price increase. That is useful evidence of adoption and pricing, but not immunity. Implant revenue was flat in constant currency, Western Europe fell 8%, gross margin dropped three points to 71% and underlying profit fell 22%. Referral bottlenecks, reimbursement, China price cuts and Sonova and MED-EL competition remain real. Services grew 6% in constant currency and soften the implant cycle.
Primary segment
Cochlear Implants
Market structure
Oligopoly
Market share
60%-65% (reported)
HHI: —
Coverage
3 segments · 6 tags
Updated 2026-08-23
Segments
Cochlear Implants
Cochlear implant systems (internal implant + external sound processors) for severe-to-profound hearing loss
Revenue
61.2%
Structure
Oligopoly
Pricing
moderate
Share
60%-65% (reported)
Peers
Services
Aftermarket sound processor upgrades, accessories, and digital/clinical support services for the Cochlear recipient installed base
Revenue
27.1%
Structure
Monopoly
Pricing
moderate
Share
—
Peers
Acoustics
Bone conduction implant systems and processors (e.g., Osia, Baha) for conductive/mixed hearing loss and single-sided deafness
Revenue
11.7%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Cochlear Implants
Cochlear implant systems (internal implant + external sound processors) for severe-to-profound hearing loss
FY2026 cochlear implant revenue was A$1,435.2M, or 61.2% of A$2,343.4M group revenue. Units rose 5%, constant-currency revenue was flat, and the Nexa System reached more than 95% of developed-market implant sales by June.
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Implant selection is a high-consequence, long-lived decision. Cochlear combines a greater-than-60% reported share with long-duration reliability data, supporting clinician and recipient trust.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- High-profile product quality/safety issues or recalls
- Competitor technology leapfrogs narrowing perceived outcomes gap
- Hospital tender / payer pressure shifting decisions toward price
Leading indicators
- Global implant unit market share trend
- Independent/clinical outcome data vs peers
- Reliability report metrics (field failure rates)
Counterarguments
- Clinician choice can be driven more by outcomes and reimbursement rules than by consumer brand
- Rivals (e.g., Advanced Bionics, MED-EL) can deliver comparable outcomes for many indications
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Large, sustained R&D spending and multi-decade implant programs support regulated platform innovation that is difficult for smaller entrants to reproduce quickly.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- R&D productivity declines or key programs fail clinically
- Competitors increase R&D and close feature/outcome gaps
- Component constraints (chipset availability) limit launch execution
Leading indicators
- R&D spend as % of sales
- Major platform launch cadence (implant + processor generations)
- Peer-reviewed clinical outcomes for new platforms
Counterarguments
- Other incumbents also invest heavily; technology leadership can shift quickly
- Some innovations may not translate into materially better clinical outcomes or pricing
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Broad country coverage and a large recipient base support clinical training, tender access, and lifetime support, but disclosed reach does not establish exclusive clinic access.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Distributor/channel disruption in key markets
- Geopolitical restrictions impacting market access or supply chains
- Clinic staffing shortages limiting procedure capacity
Leading indicators
- Number of implanting centers and surgeon engagement metrics
- Emerging market unit growth vs developed markets
- Clinic support program participation rates
Counterarguments
- Competitors can expand via distributors and partnerships; geographic reach is not fully exclusive
Services
Aftermarket sound processor upgrades, accessories, and digital/clinical support services for the Cochlear recipient installed base
FY2026 Services revenue was A$634.9M, or 27.1% of group revenue, up 6% in constant currency. Growth came from a larger eligible recipient base and Nucleus 8 replacement demand.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
More than 650,000 registered Nucleus implants create recurring upgrade and support demand; April trading confirms eligible cohorts still drive Services growth.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Longer replacement cycles as processors improve
- Reimbursement tightening or higher out-of-pocket costs delaying upgrades
- Macro cost-of-living pressure reducing discretionary upgrades
Leading indicators
- Upgrade unit volumes and Services revenue growth
- Size and growth of the eligible upgrade base (cohorts reaching replacement age)
- Recipient satisfaction levels with prior-generation processors
Counterarguments
- Services revenue can be cyclical and decline between major processor launches
- Some recipients may delay upgrades for long periods if outcomes remain acceptable
Format Lock In
Demand
Format Lock In
Strength
Durability
Confidence
Evidence
A surgically implanted Nucleus device accepts Cochlear-compatible external processors. Broad backward compatibility makes in-platform upgrades practical while cross-vendor migration requires another implant decision.
Format Lock In moat: definition, examples, and stocks
Erosion risks
- Regulatory push for interoperability / right-to-repair standards
- Third-party accessories and open wireless standards reduce switching friction
- Clinical perception that upgrade benefits are marginal vs cost
Leading indicators
- Upgrade conversion rates within eligible cohorts
- Regulatory developments affecting device interoperability
- Share of upgrades driven by public reimbursement vs out-of-pocket
Counterarguments
- Lock-in primarily protects upgrades for existing recipients; it does not eliminate competition at the initial implant decision
- Competitors can still win share by placing new implants (future installed base)
Acoustics
Bone conduction implant systems and processors (e.g., Osia, Baha) for conductive/mixed hearing loss and single-sided deafness
FY2026 Acoustics revenue was A$273.3M, or 11.7% of group revenue, up 1% in constant currency. Second-half growth improved as Osia expanded in Western Europe and Asia Pacific.
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Osia continues to produce differentiated processor and piezoelectric-platform innovation, but competing active implants and H1 volume losses show a narrower barrier than in cochlear implants.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Competitors introduce similar active bone-conduction tech and narrow differentiation
- Regulatory and MRI requirements evolve, forcing redesigns
- Category remains niche with volatile procedure volumes
Leading indicators
- Osia implant unit growth rate
- New country launches and reimbursement milestones
- Share of acoustics revenue from Osia vs legacy products
Counterarguments
- MED-EL Bonebridge and other active systems demonstrate that Osia is not the only active bone-conduction implant
- Many bone-conduction patients may opt for non-implant solutions depending on reimbursement and preferences
Format Lock In
Demand
Format Lock In
Strength
Durability
Confidence
Evidence
Osia recipients can upgrade external processors across implant generations, while moving to a competing proprietary system generally requires replacing the internal implant.
Format Lock In moat: definition, examples, and stocks
Erosion risks
- Slow processor replacement cycles limit the economic value of compatibility
- Regulatory or interoperability changes could weaken proprietary upgrade paths
Leading indicators
- Osia processor upgrade volume
- Installed Osia implant base by generation
- Backward compatibility of future processors
Counterarguments
- Lock-in protects only existing Osia recipients and does not prevent rivals from winning new implants
- Cochlear does not separately disclose Acoustics upgrade revenue
Evidence
the Cochlear Profile Plus Series delivering with 99.76% CSP within 7 years
Current cumulative-survival data provide a measurable basis for trust. Results are company-reported under industry reliability standards.
With contracting of the new system complete, market share has been improving.
Nexa adoption improved share after contracting delays. This is management-reported and does not quantify the current level.
Investment in R&D increased 9% (5% in CC) to $152.8 million
Half-year R&D was 13% of sales, demonstrating continuing scale rather than relying on a historical cumulative figure.
two studies for regulatory approval of the totally implantable cochlear implant underway
The active clinical program follows more than 20 years of development; regulatory success and commercial adoption remain uncertain.
selling in over 180 countries, with employees based in over 50 countries
Scale and geographic coverage support distribution and clinical service capability.
Showing 5 of 14 sources.
Risks & Indicators
Erosion risks
- High-profile product quality/safety issues or recalls
- Competitor technology leapfrogs narrowing perceived outcomes gap
- Hospital tender / payer pressure shifting decisions toward price
- R&D productivity declines or key programs fail clinically
- Competitors increase R&D and close feature/outcome gaps
- Component constraints (chipset availability) limit launch execution
Leading indicators
- Global implant unit market share trend
- Independent/clinical outcome data vs peers
- Reliability report metrics (field failure rates)
- Tender win rate in key markets
- R&D spend as % of sales
- Major platform launch cadence (implant + processor generations)
Research COH elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.